A variety of studies have shown that reduction of AngII expression or blockade of AT1R on the one hand, or stimulation of ACE2 on the other, may reduce the retinal damage occurring in retinal pathologies, such as glaucoma, retinal ischemia, autoimmune uveitis, or DR (Cervia et al., 2019). This evidence concerns the gene ACE2 and glaucoma.